VANI vs TNDM vs DXCM vs MDT

For growth investors, DexCom, Inc.

(DXCM) is the stronger pick with 15. 6% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Vivani Medical, Inc. (VANI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus DexCom, Inc. at 29. 0x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DexCom, Inc. wins at 2. 24x versus Medtronic plc's 35. 17x.

Over the past 5 years, Medtronic plc (MDT) delivered a total return of -29.

2%, compared to -92. 3% for Vivani Medical, Inc. (VANI). Over 10 years, the gap is even starker: DXCM returned +288. 3% versus VANI's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus Vivani Medical, Inc. 's 1. 36β — meaning VANI is approximately 221% more volatile than MDT relative to the S&P 500. On balance sheet safety, DexCom, Inc. (DXCM) carries a lower debt/equity ratio of 51% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DexCom, Inc.

(DXCM) is pulling ahead at 15. 6% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: DexCom, Inc. grew EPS 47. 2% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, DXCM leads at 17. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DexCom, Inc.

(DXCM) is the more profitable company, earning 17. 9% net margin versus -20. 2% for Tandem Diabetes Care, Inc. — meaning it keeps 17. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus -7. 7% for TNDM. At the gross margin level — before operating expenses — MDT leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, DexCom, Inc. (DXCM) is the more undervalued stock at a PEG of 2. 24x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 23. 5x for DexCom, Inc. — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TNDM: 105. 4% to $31. 77.

In this comparison, MDT (3.

7% yield) pays a dividend. VANI, TNDM, DXCM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Both have compounded well over 10 years (MDT: +24. 3%, VANI: -98. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VANI is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; DXCM is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while VANI, TNDM, DXCM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.